about
MicroRNA-182-5p targets a network of genes involved in DNA repairThe mammary myoepithelial cell--Cinderella or ugly sister?The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesionsThe diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situThe diagnosis and management of pre-invasive breast disease--current challenges, future hopesCan the stroma provide the clue to the cellular basis for mammographic density?Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.Phyllodes tumours of the breast: a consensus reviewIdentification of the familial cylindromatosis tumour-suppressor genePutting the brakes on cylindromatosis?The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromasSNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancerMolecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breastSignatures of mutational processes in human cancerThe landscape of cancer genes and mutational processes in breast cancerLoss of heterozygosity at cylindromatosis gene locus, CYLD, in sporadic skin adnexal tumours.Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast.Metaplastic breast carcinomas are basal-like tumours.Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancerGene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay.DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status.Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significanceLoss of heterozygosity in lobular carcinoma in situ of the breast.COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatmentKinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancerRad51 supports triple negative breast cancer metastasis.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Incorporating tumour pathology information into breast cancer risk prediction algorithms.HER3 and downstream pathways are involved in colonization of brain metastases from breast cancerBreast cancer prognostic classification in the molecular era: the role of histological grade.Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.Expression and function of the protein tyrosine phosphatase receptor J (PTPRJ) in normal mammary epithelial cells and breast tumors.Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicityMicroarray and histopathological analysis of tumours: the future and the past?Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis.X-inactivation patch size in human female tissue confounds the assessment of tumor clonalityInvasive lobular carcinoma of the breast: morphology, biomarkers and 'omicsSplicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary.Salivary gland-like tumours of the breast: surgical and molecular pathologyMobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.
P50
Q24633326-4EB5ADD5-B1E5-4D42-A2F1-378F2DE19BE9Q24801073-9905B559-28B3-4E95-8C3B-6540FBBE310FQ24802857-957824E0-9615-4456-A308-A97EC41CEFF3Q24803386-C91209F6-2A96-46CB-B0A7-01704F6AE2E3Q24803624-D6533FB1-828F-489B-9B26-7FE6E8E41063Q24803640-7075BF70-1694-4000-91FC-C8AE81A37ACFQ25257542-6D850AB1-2FFA-4DD1-9129-89748D2AAA05Q28079009-367FCE73-2033-43D5-AC83-54C9F7AE1321Q28145560-CF773B58-552B-4E7A-9899-2DF3891A51CEQ28166693-C5F3744A-C5EE-4E7B-8C65-A77AC1CA1BDDQ28280595-1A0BB0CF-8F17-45AC-952F-D412D7A3BF23Q28308175-4560D31B-8E19-4B7C-9878-496BB2A25979Q28345661-CBBBB45F-451C-489B-9495-79032F67A6C6Q29547191-C268019C-915C-4AE2-AFE5-C1E6A3D92204Q29614637-EC17CE70-D0F9-4EA4-AC58-7D422542ACF5Q30708238-4F706203-8449-4F03-BE21-45E4486CCBCFQ30883731-AF1A985F-FB22-4A70-9DEC-1227F78B65FBQ33250228-3F58C8AB-1D29-4EF4-A423-D2FFD174C646Q33555064-A81D699B-C179-40EB-B2BB-D129D3985698Q33622653-1FC29AE3-9D15-4957-9D7D-140474836AEAQ33708624-66929193-A1C3-4D47-9CB7-A52C5F8B81A8Q33781403-9B7D4B69-413B-4DBB-9837-3A5EF0EDF267Q33836982-08772812-8480-43A6-9FF8-B6252C77ACC2Q33877411-74B17175-9E9D-436D-BEBD-3AE0A4AB5C51Q33917578-2BC17D8A-E8B5-4E52-B846-56A0ADBD817CQ33917622-9B6CE89E-C332-4675-8B83-CEFE21C3D64CQ34046731-5C245378-4C9D-4793-A0DF-535B5C4AE19EQ34048046-1D9D763A-38E7-4EAE-9709-F983D2513CFCQ34173413-D354C5BF-EC6C-4305-8AFA-18FFAB193929Q34173440-953FBB59-4269-4333-9024-63E3E5FD7FD2Q34173460-DF9DAF5A-6E2B-4FAD-B4A6-6FAE46B754C7Q34345106-2FC39FE7-3A68-4226-89D3-60EC8541FBB8Q34495985-58A026F3-6380-43D8-A198-374AE5662B4FQ34572102-4C0E76BA-2507-4A50-A66D-820BFFCC473BQ34659939-E5A54E08-4865-407B-9EAB-C984EBA04B9CQ34868843-5E0F12B3-410F-43E6-AAC7-9AABA6CECF06Q35025646-8EBF00E5-A0D0-40D8-91C2-676327C3B981Q35121513-8BE1A981-330E-4DCE-8C71-DE35B2373AEDQ35166626-54946E17-6E6A-48A5-A360-0A8286A1B844Q35234637-192C60F2-1C11-4BDC-8EEC-0464E1523457
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sunil R Lakhani
@ast
Sunil R Lakhani
@en
Sunil R Lakhani
@es
Sunil R Lakhani
@nl
Sunil R Lakhani
@sl
type
label
Sunil R Lakhani
@ast
Sunil R Lakhani
@en
Sunil R Lakhani
@es
Sunil R Lakhani
@nl
Sunil R Lakhani
@sl
altLabel
Sunil Lakhani
@en
prefLabel
Sunil R Lakhani
@ast
Sunil R Lakhani
@en
Sunil R Lakhani
@es
Sunil R Lakhani
@nl
Sunil R Lakhani
@sl
P1053
I-1970-2018
P106
P31
P496
0000-0003-4067-2760